Safety System Articles & Analysis: Older
72 news found
A Centers for Disease Control and Prevention (CDC) report published on October 3, 2024, linked Burkholderia multivorans infections to ice machines in multiple healthcare facilities in the western United States. This post summarizes key findings, implications, and recommended practices for healthcare providers to ensure patient ...
These derivatives play a crucial role in drug formulation and delivery systems in the biopharmaceutical sector. The company also provides top-tier CDMO services, supporting clients through every phase of development, ensuring that their unique manufacturing needs are met with precision and efficiency. ...
Protheragen-ING Lab, a well-known and reputable Good Laboratory Practices (GLP) service provider, has recently unveiled its cutting-edge medical device services. With a track record of excellence and reliability in providing high-quality services to the pharmaceutical and biotechnology industries, Protheragen-ING Lab is now expanding its offerings to include comprehensive solutions for medical ...
Boston: “According to the latest BCC Research study, the demand for EMI/RFI: Materials and Technologies is estimated to increase from $7.4 billion in 2023 to reach $9.2 billion by 2028, at a compound annual growth rate (CAGR) of 4.6% from 2023 through 2028.” This comprehensive report delves into the dynamic landscape of the EMI/RFI materials and technologies market, meticulously ...
With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development process and ensure the safety and efficacy of potential new therapeutics. ...
Vizient serves approximately 97% of the nation's Academic Medical Centers, more than 50% of the nation's acute care health system, and serves more than 20% of the nation's ambulatory market. This contract enables TOMI to supply SteraMist systems to a wide range of healthcare providers, including academic medical centers, pediatric facilities, and community health ...
After the fat cells have died, they are broken down and removed by the metabolic system over a period of time, resulting in the breakdown and removal of fat, accompanied by a beneficial skin tissue tightening effect. ...
“This important accreditation is reflective of Castle’s commitment to excellence, safety and quality, driven by our dedicated laboratory team,” said Kristen Oelschlager, chief operating officer of Castle Biosciences. ...
Thaw More Plasma Faster with ZipThaw® Traditionally, plasma thawing is done in hot water baths which are slow, messy, and outdated. With their slow thawing to imprecise temperatures, time taken for warm up, and extensive maintenance and clean up needs, water baths make it impossible to maintain high plasma throughput levels. Now there’s an easier way to thaw more plasma, faster. ...
Over 58 million vials/pre-filled syringes of Eylea have been sold since its launch worldwide, with more than 8 million patient-years of experience and a well-established ocular and systemic safety profile. Aflibercept 8 mg is investigational, and its safety and efficacy have not yet been evaluated by any regulatory authority. ...
ByBayer AG
The study evaluates short and long-term clinical outcomes of patients treated with the FlowTriever system, including safety results, on-table hemodynamic improvements, and hospital resource utilization. ...
Among important changes like a new risk-based classification system and a unique product numbering system to simplify the traceability of products within the supply chain is also a more in-depth involvement of notified bodies, such as TÜV SÜD Product Service GmbH, for the conformity assessment. Stricter requirements for technical documentation and ...
ATLANTA, Georgia – The early success of Linear Health Sciences in developing its Orchid™ Safety Release Valve to prevent unwanted dislodgement of IV catheters was highlighted in a panel discussion at the recent annual conference of the Southeastern Medical Device Association (SEMDA). Dan Clark, co-founder and Chief Marketing Officer of Linear Health Sciences, represented the company ...
OKLAHOMA CITY, Oklahoma – Linear Health Sciences, developer of the Orchid™ Safety Release Valve (SRV), announced that it has received a substantial grant to work with the Global Center for Medical Innovation. ...
OKLAHOMA CITY – Linear Health Sciences today announced that the United States Patent and Trademark Office has issued the company’s first patent related to its flagship product, the Orchid Safety Release Valve™. US Patent No. 9,861,805 B2 covers wide-ranging claims behind the needless connector for use in medical access devices such as IV catheters. “The patent issuance ...
Portsmouth, N.H. – IV dislodgement is a near-daily problem for clinicians and their patients, according to a recent focus group of vascular access experts. The clinicians also reported there is a need for better technology to mitigate the potentially serious consequences of frequent IV dislodgements. “This research discussion addressed a frustrating problem that those of us in ...
The system allows for uniform expansion of the stent to maximize lumen diameter and may reduce acute vessel recoil and dissections. Engineered to fulfill an unmet clinical need in treating patients suffering from Critical Limb Ischemia (CLI), the Temporary Spur Stent System consists of a unique, retrievable nitinol stent system with radially ...
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and ...
CARDIONOVUM announced today the first Signature Randomized Clinical Trial patient enrolment. On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled. Dr. Ralf Langhoff, P.I. of the study, stated “I believe that this randomized study will confirm, once more, the efficacy and the safety of the Legflow® DCB in the daily treatment of ...
A further 29 patients from the Roll-In Cohort were also implanted with the alfapump and will be included in the overall safety analysis. Importantly, a preliminary interim analysis[1] of patient survival following alfapump implantation in the Roll-In Cohort indicated a mean survival probability of 70% at 12 months. ...